The Fatty Liver Epidemic in Singapore
Non-alcoholic fatty liver disease (NAFLD) affects an estimated 40–45% of Singaporeans — one of the highest rates in Asia. It is strongly associated with obesity, type 2 diabetes, hypertension, and high cholesterol (metabolic syndrome). Many patients are unaware they have it until abnormal liver enzymes or an incidental ultrasound finding prompts investigation.
NAFLD vs NASH: Understanding the Spectrum
| Stage | What It Means | Management |
|---|---|---|
| Simple Steatosis (NAFLD) | Fat in liver cells; no significant inflammation; low risk of progression | Lifestyle modification is highly effective |
| NASH (Non-Alcoholic Steatohepatitis) | Fat + inflammation + hepatocyte damage; risk of fibrosis and cirrhosis | Weight loss >7–10%; specific pharmacotherapy under evaluation |
| NASH with Fibrosis | Scar tissue in liver; varies from F1 (mild) to F4 (cirrhosis) | Same as NASH plus close monitoring; avoid hepatotoxins |
| NASH Cirrhosis | Advanced scarring; portal hypertension; liver failure risk; HCC risk | Hepatology care; portal hypertension management; HCC surveillance |
| Hepatocellular Carcinoma | Liver cancer arising from NASH cirrhosis | Multi-disciplinary oncology management |
Assessment Tools
- FibroScan (transient elastography): Non-invasive measurement of liver stiffness (fibrosis) and controlled attenuation parameter (fat). Quick, painless, performed in clinic. Best available non-invasive test for fibrosis staging. $200–$500 at private hepatology centres.
- Liver ultrasound: Detects fatty liver when >33% of liver is involved. Cannot quantify fat or detect early fibrosis reliably.
- Blood fibrosis markers: FIB-4 index (calculated from age, ALT, AST, platelets), NAFLD fibrosis score — used to stratify risk without imaging.
- MR spectroscopy/PDFF: Most accurate non-invasive quantification of liver fat — used in research and selected clinical scenarios.
- Liver biopsy: Definitive diagnosis but invasive; reserved for cases where non-invasive tests are inconclusive or where specific diagnosis changes management.
Treatment
No pharmacological treatment is specifically approved for NAFLD/NASH in Singapore as of 2026 (resmetirom/Rezdiffra has FDA approval in the US — watch for approval updates). Cornerstone management:
- Weight loss: 7–10% weight reduction reduces liver fat significantly; 10%+ can resolve NASH in many patients. Dietary caloric restriction + exercise.
- Diet: Mediterranean diet, low in refined carbohydrates and added sugars. Minimise fructose and alcohol.
- Exercise: Both aerobic and resistance training independently reduce liver fat, even without weight loss.
- Metabolic syndrome management: Blood sugar, lipid, and blood pressure control — statins are safe in NAFLD and may be beneficial.
- Bariatric surgery: For eligible obese patients with NASH — achieves the greatest weight loss and fibrosis regression. KYM Surgery and bariatric specialists in Singapore offer this.
See our researched shortlist: subspecialty focus, credentials and clinic websites, checked against public records.
View the shortlist →Yes. Non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver can both be reversed with appropriate lifestyle changes — particularly weight loss of 7–10% of body weight, which can significantly reduce liver fat and inflammation. Even without weight loss, reducing refined carbohydrates, added sugars, and alcohol, combined with regular exercise, can improve liver health substantially.
Fatty liver is often diagnosed incidentally on ultrasound or CT scan, or found through elevated liver enzymes (ALT, AST) on a blood test. Formal assessment requires: liver function tests (LFTs), fasting glucose/HbA1c, lipid profile, ultrasound (detects fat if >33% of liver is affected), and sometimes FibroScan (transient elastography) to assess fibrosis/stiffness. Liver biopsy is the gold standard for staging but is used selectively.
NASH (Non-Alcoholic Steatohepatitis) is an advanced form of NAFLD where fat accumulation is accompanied by liver inflammation and hepatocyte damage. NASH can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (liver cancer). It is diagnosed on liver biopsy. Singapore has one of Asia's highest rates of NASH due to its high prevalence of obesity, diabetes, and metabolic syndrome.
For simple NAFLD without elevated enzymes or advanced fibrosis, GP management with lifestyle counselling may be sufficient. However, patients with persistently elevated liver enzymes, suspected NASH, FibroScan showing significant fibrosis (F2+), or any features of metabolic syndrome should be evaluated by a hepatologist or gastroenterologist for full assessment and management.
Liver function blood tests: $30–$80 (GP/polyclinic). Liver ultrasound: $150–$400. FibroScan: $200–$500. Specialist hepatology consultation at a private clinic: $150–$300. Combined liver assessment package at a private gastroenterology/hepatology clinic: $400–$800. Liver biopsy: $2,000–$5,000.